Symbols / CBIO
CBIO Chart
About
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 369.01M |
| Enterprise Value | 119.78M | Income | -71.47M | Sales | — |
| Book/sh | 5.76 | Cash/sh | 6.82 | Dividend Yield | — |
| Payout | — | Employees | 41 | IPO | — |
| P/E | — | Forward P/E | -3.66 | PEG | — |
| P/S | — | P/B | 2.10 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.62 |
| Current Ratio | 3.62 | Debt/Eq | 1.49 | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | -3.31 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 07:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 27.56M |
| Shs Float | 2.86M | Short Float | — | Short Ratio | 8.39 |
| Short Interest | — | 52W High | 29.00 | 52W Low | 8.72 |
| Beta | — | Avg Volume | 197.90K | Volume | 29.53K |
| Target Price | $30.14 | Recom | Strong_buy | Prev Close | $12.65 |
| Price | $12.12 | Change | -4.19% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.14
Mean price target
2. Current target
$12.12
Latest analyst target
3. DCF / Fair value
$30.14
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$12.12
Low
$22.00
High
$35.00
Mean
$30.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | init | Guggenheim | — → Buy | $35 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-25 | init | Jefferies | — → Buy | $26 |
| 2025-08-11 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2025-07-14 | init | Wedbush | — → Outperform | $27 |
| 2025-06-25 | init | Stifel | — → Buy | $28 |
| 2025-06-18 | init | LifeSci Capital | — → Outperform | $22 |
- Gossamer Bio stock tumbles 80% on trial miss - Investing.com Mon, 23 Feb 2026 13
- $CBIO stock is up 15% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Feb 2026 19
- Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits Mon, 23 Feb 2026 16
- Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena hu, 12 Feb 2026 08
- Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock² ue, 24 Feb 2026 10
- Experimental cancer antibody CR-001 enters global trial in advanced solid tumors - Stock Titan Wed, 18 Feb 2026 12
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 30 Jan 2026 08
- Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data - Trefis Wed, 11 Feb 2026 11
- Updated: Upstream Bio's stock slides on Phase 2 severe asthma data - Endpoints News Wed, 11 Feb 2026 11
- Crescent Biopharma (CBIO) Stock: Chasing The Summit Hype - Seeking Alpha Mon, 18 Aug 2025 07
- Why Is Crescent Biopharma Stock (CBIO) Up Today? - TipRanks hu, 04 Dec 2025 08
- Why Belite Bio Stock Soared on Monday - The Motley Fool Mon, 01 Dec 2025 08
- Barclays cuts Gossamer Bio stock rating on trial results - Investing.com South Africa ue, 24 Feb 2026 16
- ‘Zombie’ biotech buyer Xoma to acquire Generation Bio - BioPharma Dive ue, 16 Dec 2025 08
- Crescent Biopharma (Nasdaq: CBIO) raises $185M to fund 3 solid tumor programs into 2028 - Stock Titan hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 55117 | — | — | Stock Award(Grant) at price 0.00 per share. | BRUMM JOSHUA T. | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 1 | 12378 | — | — | Stock Award(Grant) at price 0.00 per share. | LYNCH RYAN | Officer and Treasurer | — | 2025-12-15 00:00:00 | D |
| 2 | 19422 | — | — | Stock Award(Grant) at price 0.00 per share. | SCALZO RICHARD WILLIAM | Chief Financial Officer | — | 2025-12-15 00:00:00 | D |
| 3 | 25507 | — | — | Stock Award(Grant) at price 0.00 per share. | MCNEILL JONATHAN | President | — | 2025-12-15 00:00:00 | D |
| 4 | 22714 | — | — | Stock Award(Grant) at price 0.00 per share. | DOUGHTY CHRISTOPHER GRANT | Officer | — | 2025-12-15 00:00:00 | D |
| 5 | 21298 | — | — | Stock Award(Grant) at price 0.00 per share. | IM ELLIE EUNKYUNG | Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 18422 | — | — | Stock Award(Grant) at price 0.00 per share. | BISPHAM BARBARA HARLIN | General Counsel | — | 2025-12-15 00:00:00 | D |
| 7 | 22507 | — | — | Stock Award(Grant) at price 0.00 per share. | PINKAS JAN | Officer | — | 2025-12-15 00:00:00 | D |
| 8 | 1360000 | 18237600 | — | Purchase at price 13.41 per share. | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-04 00:00:00 | I |
| 9 | 1379119 | 315262 | — | Sale at price 0.22 - 0.24 per share. | INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-07-30 00:00:00 | I |
Financials
No income statement data available.
| Line Item | 2024-12-31 |
|---|---|
| OrdinarySharesNumber | 19.50M |
| ShareIssued | 19.50M |
| NetDebt | 2.72M |
| TotalDebt | 37.48M |
| TangibleBookValue | -15.48M |
| InvestedCapital | 22.00M |
| WorkingCapital | 25.19M |
| NetTangibleAssets | -15.48M |
| CommonStockEquity | -15.48M |
| TotalCapitalization | 22.00M |
| TotalEquityGrossMinorityInterest | -15.48M |
| StockholdersEquity | -15.48M |
| RetainedEarnings | -17.87M |
| AdditionalPaidInCapital | 2.39M |
| CapitalStock | 1.00K |
| CommonStock | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 51.10M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 41.48M |
| PreferredSecuritiesOutsideStockEquity | 4.00M |
| LongTermDebtAndCapitalLeaseObligation | 37.48M |
| LongTermDebt | 37.48M |
| CurrentLiabilities | 9.61M |
| OtherCurrentLiabilities | 61.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 15.00K |
| PayablesAndAccruedExpenses | 9.54M |
| CurrentAccruedExpenses | 2.21M |
| InterestPayable | 852.00K |
| Payables | 7.33M |
| DuetoRelatedPartiesCurrent | 7.22M |
| AccountsPayable | 107.00K |
| TotalAssets | 35.62M |
| TotalNonCurrentAssets | 813.00K |
| NonCurrentDeferredAssets | 813.00K |
| CurrentAssets | 34.80M |
| OtherCurrentAssets | 38.00K |
| CashCashEquivalentsAndShortTermInvestments | 34.77M |
| CashAndCashEquivalents | 34.77M |
| CashFinancial | 34.77M |
No cash flow data available.
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|